Last reviewed · How we verify
Early Dual Antiplatelet Therapy
Early dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.
Early dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events. Used for Acute ischemic stroke (early intervention), Acute coronary syndrome.
At a glance
| Generic name | Early Dual Antiplatelet Therapy |
|---|---|
| Also known as | Ticagrelor and Aspirin |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Dual antiplatelet therapy (DAPT) |
| Target | Cyclooxygenase (COX) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This therapeutic approach typically combines aspirin (which inhibits cyclooxygenase and thromboxane A2 production) with a P2Y12 receptor antagonist (such as clopidogrel, prasugrel, or ticagrelor) to provide complementary antiplatelet effects. The dual mechanism targets multiple pathways of platelet activation, providing more potent inhibition of clot formation compared to monotherapy, particularly in acute cardiovascular events.
Approved indications
- Acute ischemic stroke (early intervention)
- Acute coronary syndrome
Common side effects
- Bleeding/hemorrhage
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
Key clinical trials
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke (PHASE3)
- Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE (PHASE3)
- OCT-based DAPT Cessation in HBR Patients (NA)
- Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease (PHASE4)
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
- Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction (PHASE4)
- Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Early Dual Antiplatelet Therapy CI brief — competitive landscape report
- Early Dual Antiplatelet Therapy updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI